Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

This is What Happened With Delcath

Shares of Delcath Systems Inc. (Nasdaq: DCTH) fell more than 40% yesterday after U.S. Food and Drug Administration (FDA) staffers said the company's experimental liver-cancer-treatment system would probably require another round of clinical trials.

The surprise recommendation was contained in a briefing document that was posted yesterday on the FDA's Web site. The document outlines the key issues that the FDA's Oncologic Drugs Advisory Committee (ODAC) will work through with Delcath at a meeting that is scheduled for tomorrow (Thursday).

  1. buffalokandravi@aol.com | May 20, 2013

    How dead is this DCTH or do you see a brightside we don't know about?

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK